Lord, Abbett & Co
GNMK

Lord, Abbett & Co’s GenMark Diagnostics, Inc GNMK Stock Holding History

Lord, Abbett & Co’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-698,960
Closed -$10.2M – 719
2020
Q4 		$10.2M Buy
698,960
+107,727
+18% +$1.43M 0.03% 518
2020
Q3 		$8.4M Buy
591,233
+164,605
+39% +$2.52M 0.03% 499
2020
Q2 		$6.28M Buy
+426,628
New +$4.33M 0.02% 545

Other funds holding GNMK

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lord, Abbett & Co's GNMK Position: Q1 2021 in Review

Lord, Abbett & Co sold out of GenMark Diagnostics, Inc (GNMK) in Q1 2021, closing a stake of 698,960 shares — an estimated $10.2M sold.

Lord, Abbett & Co first reported a position in GNMK in Q2 2020 and held it in 3 quarters. The position peaked at $10.2M in Q4 2020. 164 funds tracked by Wall St. Rank hold GNMK as of Q1 2021.

  • Lord, Abbett & Co reported no remaining GenMark Diagnostics, Inc position as of Q1 2021 after selling out during the quarter.
  • Lord, Abbett & Co sold 698,960 GenMark Diagnostics, Inc shares in Q1 2021, an estimated $10.2M.
  • Lord, Abbett & Co first reported a position in GenMark Diagnostics, Inc in Q2 2020 and held it in 3 quarters.
  • Lord, Abbett & Co's GenMark Diagnostics, Inc position peaked at $10.2M in Q4 2020.
  • 164 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q1 2021.

Based on Lord, Abbett & Co's 13F filing for Q1 2021, filed 11 May 2021.